Introduction
Phospholipid (PL) antibodies are a heterogeneous group of autoantibodies binding to phospholipid-like antigens like cardiolipin (CL) and phosphatidylserine (PS). b 2 -Glycoprotein I (b 2 -GpI) is a plasma protein binding to negatively charged macromolecules and structures, such as phospholipids, DNA, platelets and mitochodria.
1 b 2 -GpI mRNA is also expressed in neurons, astrocytes and in brain endothelial cells. 2 Phospholipid and b 2 -GpI antibodies have reported to bind to neuronal tissue. [3] [4] [5] [6] High systemic titres of these antibodies are characteristic to primary antiphospholipid syndrome (APS), with systemic manifestations of recurrent spontaneous pregnancy loss, thrombosis, thrombocytopenia, as well as various central nervous system (CNS) symptoms. 7 These neurological symptoms include chorea, psychosis, depression, cognitive dysfunction and dementia. 7, 8 Seizures are relatively well characterized neurological symptoms associated with PL antibodies, especially in patients with systemic lupus erythematosus (SLE). 9, 10 However, PL antibodies have been found in patients with epilepsy without SLE. [11] [12] [13] In the present study we aimed to study the role of CL, b 2 -GpI and antinuclear (ANA) autoantibodies in different types of developmental disorders. We have especially focused on whether these antibodies are associated with the level of cognitive dysfunction, etiological factors underlying intellectual disability and epilepsy, specific epilepsy syndromes or frequency of seizures.
Materials and methods
The inclusion criteria for the study were a developmental disorder due to a genetic or structural cause with at least five-year history of refractory seizures despite of adequate treatment. Of 77 consecutively recruited patients, written informed consent was obtained from guardians of 74 patients. A total of 70 healthy blood donors were used as control subjects.
The patients' blood samples were taken in connection to routine laboratory tests. We used commercially available assays to determine CL antibody titres (Quanta Lite ACA IgG and IgM; B 2 GPI, IgG; INOVA Diagnostics, San Diego, CA, USA). Patients and controls with positive results in IgG-CL assay were also tested for Pearson Chi-square test, Fisher's exact test and logistic regression analysis served in statistical analysis. A p value of 0.05 or less was considered statistically significant. The ethical committee of Tampere University Hospital approved the study design.
Results

Clinical data
The study group comprised of 74 patients (31 females and 43 males, age range 15-61, mean age 35 years) and 70 controls (age range 16-65 years, mean age 36 years). All patients had undergone a detailed analysis of their condition including video-EEG, brain MRI as well as consultation of a clinical geneticist and psychologist. The patients' etiological diagnoses in detail (classified into genetic syndromes, genetic diseases, genetic and/or acquired conditions, cortical dysgenesias and acquired disorders) are presented in Table  1 and epilepsy diagnoses in Table 2 . Sixty-four patients (86%) experienced first seizures during childhood or adolescence. Twelve patients showed hippocampal sclerosis (eight had an acquired encephalopathia and four a genetic disorder) in brain MRI. Two patients acted at subnormal intelligence, 7 at the level of mild (IQ 69-50), 4 at moderate (IQ 49-35), 30 at severe (IQ 34-20), and 31 at the level of profound (IQ < 20) intellectual disability (ID). Nine patients suffered from 1 to 11 seizures yearly, 27 from 1 to 3 seizures monthly, 21 from 1 to 6 seizures weekly, and 17 patients from daily seizures.
All patients except one were on polytherapy. Fifty-five patients received valproate, 28 topiramate, 25 lamotrigine, 16 oxcarbatsepine, 10 levetirasetame, 9 carbamazepine, 9 clobatsame, 8 clonazepam, 7 vigabatrine, 6 gabapentine, 5 phenytoin, 2 ethosuximide, 2 azetatsolamide, and 2 phenobarbitale.
Antibody tests 3.2.1. Patients and controls
Positive titres of IgM-CL antibodies were more frequent in patients (46%) than in controls (20%) (p < 0.001; Fisher's exact test, Table 2 ). The prevalence of positive IgG-CL antibodies did not differ between patients (16%) and controls (13%), however, 10% of patients had b 2 -GpI antibodies while no b 2 -GpI antibodies were detected in controls (p < 0.05; Fisher's exact test, Table 2 ). The prevalence of ANA antibodies was the same among patients and controls. The patient's age, gender, onset age of epilepsy or medication did not relate to the prevalence of PL or ANA antibodies.
Etiology of developmental disorder
The prevalence of positive antibody titres in different etiological groups is presented in Table 2 . Autoantibodies were not specific to any of the etiological groups, but were distributed within all groups studied. The prevalence of positive antibodies was highly dependent of the number of patients in each group (Table 2) .
Epilepsy syndrome and seizure frequency
Autoantibodies studied were not specific to any of the epileptic syndromes. There were no statistically significant differences between epileptic syndromes, although IgM-CL antibodies were most frequent in Lennox-Gastaut syndrome ( Table 2) . Prevalence of antibodies was highly dependent of the group size. We found no association between positive antibodies and presence of hippo- Table 1 Etiological groups and specific diagnoses of the 74 study patients.
Etiological groups Diagnosis
Genetic syndromes (15) Down syndrome (4), X-linked mental retardation (3), trisomy 15q (2), Angelman (1), deletion 6q (1), autosomal dominant familial disorder (1), Kabuki (1), unidentified dysmorphic syndrome (2) Genetic diseases (7) Aspartylglucosaminuria (2), spinocerebellar ataxia (1), neurofibromatosis type 2 (1), MELAS (1), x-linked familial (1), Dravet (1) Genetic/acquired condition (6) Infantile autism (4), unspecific intellectual disability with generalized epilepsy (2) Cortical dysgenesias (15) Polymicrogyria (6), temporal dysmyelination (4), microcephalia (2), schizenkefalia (1), pachygyria (1), lissenencephalia (1) Acquired encephalopathias (31) post-asphyxial (11), post-infectious (8), mesial temporal sclerosis (5), early severe epilepsy (4) and post-traumatic (3) Table 2 Prevalence of positive antibodies in controls and patients according to etiology and epilepsy syndrome. campal sclerosis on MRI. Prevalence of IgM-CL antibodies increased concomitantly with increasing seizure frequency compared to controls (Table 3) . b 2 -GpI and ANA antibodies were not significantly associated to seizure frequency.
Intellectual disability
To test association between antibody prevalence and intellectual disability, subnormal, mild and moderate levels of disability were pooled as a single group (IQ > 35; n = 13), severe as one group (IQ 20-34; n = 30) and profound disability as one group (IQ < 20; n = 31). The prevalence of positive IgM-CL antibodies increased with increasing intellectual disability ( Table 4) . IgG-CL antibodies were also more frequent in profound intellectual disability compared with controls (Table 4 ). The prevalence of b 2 -GpI antibodies increased significantly with increasing intellectual disability (Table  4) . ANA antibodies were not significantly associated with the level of cognitive impairment (data not shown).
Antibody titres
Among 34 IgM-CL positive patients 15 (44%) were regarded as moderately positive (21-80 MPL units) and within 14 control subjects 5 (36%) were moderately positive. Other positive patients and control subjects had low positive titres. Among IgG-CL positive patients 7 out of 12 (58%) were regarded as moderately positive (21-80 GPL units), however, in controls, IgG-CL was moderately positive only in 3 out of 9 subjects (33%). Other patients and control subjects had low positive titres. Highest detected CL titres (moderate) were not found to be associated to any specific diagnosis or etiology. Observed titres for b 2 -GpI antibodies were between 39 and 82 international SGU units.
Discussion
In the present study we found that in developmental disorders manifesting with epilepsy the prevalence of IgM-CL and b 2 -GpI antibodies is significantly higher compared to healthy blood donors. Interestingly, increase in seizure frequency increased concomitantly the risk for positive IgM-CL antibodies. Finally, we found that increasing severity of intellectual disability increased significantly the risk for positive IgM-CL, IgG-CL and b 2 -GpI antibodies.
Previously, IgG-CL antibodies were found in patients with recent seizures, but not in patients who were seizure free for a month prior to sampling. 13 In a large population based study by Ranua et al. authors described that patients with partial epilepsy with at least one seizure per month were more likely to have positive IgG-CL antibodies than patients with lower seizure frequency. 14 The authors of these studies suggested that production of PL antibodies reflects secondary immune system activation related to seizures. Our results further support this hypothesis.
Whether autoantibodies are associated with the developmental disorders or epilepsy as such cannot be fully evaluated in the present study since patients with developmental disorder without epilepsy were not included in the study. However, the prevalence of CL and b 2 -GpI antibodies in our patients with developmental disorder and refractory epilepsy is in accordance with a study in adult patients with localization related epilepsy. 11 We therefore conclude that epilepsy and seizures is more clearly associated with PL antibodies than developmental disorders as per se.
The pathophysiological relevance of PL antibodies in developmental disorders and refractory epilepsy is controversial. In SLE, moderate or high titres of CL-IgG are associated with seizures. 9 SLE patients with positive IgG-CL antibodies have 3.7 times higher risk for seizures compared to CL antibody negative patients, 10 suggesting that antibodies may indeed decrease seizure threshold level. PL antibodies have been shown to depolarize neurons in vitro. 15 Moreover, CL antibodies have been described to reduce gamma-aminobutyric acid (GABA) mediated inhibition of neurons. 16 PL antibodies have suggested to cause epilepsy in a few pediatric patients. 17 Impairment of cognitive functions in SLE patients with PLantibodies is well documented. 8 We found that the prevalence of Table 3 The prevalence of CL and b 2 -GpI antibodies in patients and controls according to seizure frequency. Statistical difference between patients and controls: *, p < 0,05; Fisher's exact). Table 4 The prevalence of CL and b 2 -GpI antibodies in patient groups according to the severity of intellectual disability. IgG/M-CL and b 2 -GpI antibodies was considerably high in patients with most severe forms of intellectual disability compared to moderate to subnormal impairment. It can be hypothesized that CL and b 2 -GpI antibodies may serve as markers of secondary neuronal tissue injury manifesting with cognitive impairment. However, further studies are needed to confirm our findings. Several factors limit the interpretation of our data. Classification of patients into smaller heterogeneously sized subgroups limits the evaluation of antibody prevalence, especially if antibody prevalence is low (Ig-CL, b 2 -GpI and ANA). IgM-CL had clearly highest prevalence both in healthy controls and all patient groups, enabling most reliable calculations. However, the pathophysiological relevance of IgM-CL antibodies in epilepsy is entirely unknown, and is most likely limited due to its relatively high prevalence in healthy controls. However, we suggest that increased IgM-CL prevalence in patients with frequent seizures reflects host's non-specific immunological activation as a response to frequent seizures.
As a conclusion, our results as well as previous data indicate that developmental disorders with refractory epilepsy are associated with low to moderate titres of CL and b 2 -GpI antibodies.
High seizure frequency and especially severe intellectual disability were significantly associated to positive antibody titres. Observed immunological activation is most likely secondary phenomenon due to high seizure frequency and neuronal tissue damage.
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